Rob Koremans, Recordati CEO
Recordati acquires EUSA Pharma and its 4 rare disease drugs, but analysts question strategy behind the deal
An Italian pharma company engineered a nearly $850 million buyout last week looking to expand its rare disease portfolio and further soak up parts of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
